Near complete pathologic response to PD-1 inhibitor and radiotherapy in a patient with locally advanced pancreatic ductal adenocarcinoma

Patrick M. McCarthy; Matthew J. Rendo; Matthew D. Uy; Alexandra M. Adams; Anne E. O’Shea; Daniel William Nelson; Joshua L. Fenderson; Katherine M. Cebe; Robert W. Krell; Guy T. Clifton; George E. Peoples; Timothy J. Vreeland

doi:10.2147/OTT.S311661

Near complete pathologic response to PD-1 inhibitor and radiotherapy in a patient with locally advanced pancreatic ductal adenocarcinoma

Patrick M. McCarthy^*, Matthew J. Rendo, Matthew D. Uy, Alexandra M. Adams, Anne E. O’Shea, Daniel William Nelson, Joshua L. Fenderson, Katherine M. Cebe, Robert W. Krell, Guy T. Clifton, George E. Peoples, Timothy J. Vreeland

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Pancreatic ductal adenocarcinoma (PDAC) remains deadly despite advances in systemic therapies and surgical techniques. While there is increasing utilization of immune therapies across diverse cancer types, PDAC remains generally resistant to these treatments. We report a case of locally advanced PDAC treated with preoperative radiation and anti-PD-1 immunotherapy guided by preoperative PD-L1 tumor analysis. After 4 months of preoperative therapy, the patient was submitted to resection, demonstrating a near-complete pathologic response on final tumor analysis. We will discuss the relevant literature and current state of immunotherapeutics for PDAC.

Original language	English
Pages (from-to)	3537-3544
Number of pages	8
Journal	OncoTargets and Therapy
Volume	14
DOIs	https://doi.org/10.2147/OTT.S311661
State	Published - 2021
Externally published	Yes

Keywords

Complete response
Immune checkpoint inhibitor
Locally advanced
PD-L1
Pancreatic cancer
Pembrolizumab

Access to Document

10.2147/OTT.S311661

Cite this

McCarthy, P. M., Rendo, M. J., Uy, M. D., Adams, A. M., O’Shea, A. E., Nelson, D. W., Fenderson, J. L., Cebe, K. M., Krell, R. W., Clifton, G. T., Peoples, G. E., & Vreeland, T. J. (2021). Near complete pathologic response to PD-1 inhibitor and radiotherapy in a patient with locally advanced pancreatic ductal adenocarcinoma. OncoTargets and Therapy, 14, 3537-3544. https://doi.org/10.2147/OTT.S311661

@article{21bd7ee238e9459399270bde91d3273a,

title = "Near complete pathologic response to PD-1 inhibitor and radiotherapy in a patient with locally advanced pancreatic ductal adenocarcinoma",

abstract = "Pancreatic ductal adenocarcinoma (PDAC) remains deadly despite advances in systemic therapies and surgical techniques. While there is increasing utilization of immune therapies across diverse cancer types, PDAC remains generally resistant to these treatments. We report a case of locally advanced PDAC treated with preoperative radiation and anti-PD-1 immunotherapy guided by preoperative PD-L1 tumor analysis. After 4 months of preoperative therapy, the patient was submitted to resection, demonstrating a near-complete pathologic response on final tumor analysis. We will discuss the relevant literature and current state of immunotherapeutics for PDAC.",

keywords = "Complete response, Immune checkpoint inhibitor, Locally advanced, PD-L1, Pancreatic cancer, Pembrolizumab",

author = "McCarthy, {Patrick M.} and Rendo, {Matthew J.} and Uy, {Matthew D.} and Adams, {Alexandra M.} and O{\textquoteright}Shea, {Anne E.} and Nelson, {Daniel William} and Fenderson, {Joshua L.} and Cebe, {Katherine M.} and Krell, {Robert W.} and Clifton, {Guy T.} and Peoples, {George E.} and Vreeland, {Timothy J.}",

note = "Publisher Copyright: {\textcopyright} 2021 McCarthy et al.",

year = "2021",

doi = "10.2147/OTT.S311661",

language = "English",

volume = "14",

pages = "3537--3544",

journal = "OncoTargets and Therapy",

issn = "1178-6930",

}

McCarthy, PM, Rendo, MJ, Uy, MD, Adams, AM, O’Shea, AE, Nelson, DW, Fenderson, JL, Cebe, KM, Krell, RW, Clifton, GT, Peoples, GE & Vreeland, TJ 2021, 'Near complete pathologic response to PD-1 inhibitor and radiotherapy in a patient with locally advanced pancreatic ductal adenocarcinoma', OncoTargets and Therapy, vol. 14, pp. 3537-3544. https://doi.org/10.2147/OTT.S311661

TY - JOUR

T1 - Near complete pathologic response to PD-1 inhibitor and radiotherapy in a patient with locally advanced pancreatic ductal adenocarcinoma

AU - McCarthy, Patrick M.

AU - Rendo, Matthew J.

AU - Uy, Matthew D.

AU - Adams, Alexandra M.

AU - O’Shea, Anne E.

AU - Nelson, Daniel William

AU - Fenderson, Joshua L.

AU - Cebe, Katherine M.

AU - Krell, Robert W.

AU - Clifton, Guy T.

AU - Peoples, George E.

AU - Vreeland, Timothy J.

PY - 2021

Y1 - 2021

N2 - Pancreatic ductal adenocarcinoma (PDAC) remains deadly despite advances in systemic therapies and surgical techniques. While there is increasing utilization of immune therapies across diverse cancer types, PDAC remains generally resistant to these treatments. We report a case of locally advanced PDAC treated with preoperative radiation and anti-PD-1 immunotherapy guided by preoperative PD-L1 tumor analysis. After 4 months of preoperative therapy, the patient was submitted to resection, demonstrating a near-complete pathologic response on final tumor analysis. We will discuss the relevant literature and current state of immunotherapeutics for PDAC.

AB - Pancreatic ductal adenocarcinoma (PDAC) remains deadly despite advances in systemic therapies and surgical techniques. While there is increasing utilization of immune therapies across diverse cancer types, PDAC remains generally resistant to these treatments. We report a case of locally advanced PDAC treated with preoperative radiation and anti-PD-1 immunotherapy guided by preoperative PD-L1 tumor analysis. After 4 months of preoperative therapy, the patient was submitted to resection, demonstrating a near-complete pathologic response on final tumor analysis. We will discuss the relevant literature and current state of immunotherapeutics for PDAC.

KW - Complete response

KW - Immune checkpoint inhibitor

KW - Locally advanced

KW - PD-L1

KW - Pancreatic cancer

KW - Pembrolizumab

UR - http://www.scopus.com/inward/record.url?scp=85107988532&partnerID=8YFLogxK

U2 - 10.2147/OTT.S311661

DO - 10.2147/OTT.S311661

M3 - Article

AN - SCOPUS:85107988532

SN - 1178-6930

VL - 14

SP - 3537

EP - 3544

JO - OncoTargets and Therapy

JF - OncoTargets and Therapy

ER -

Near complete pathologic response to PD-1 inhibitor and radiotherapy in a patient with locally advanced pancreatic ductal adenocarcinoma

Abstract

Keywords

Access to Document

Fingerprint

Cite this